Analysis and therapeutic research for growth impairment accompanied with chronic inflammatory syndrome of children as dysregulation of proinflammatory cytokines

促炎细胞因子失调所致儿童慢性炎症综合征生长障碍分析及治疗研究

• 批准号: 23591546
• 负责人: YOKOTA Shumpei
• 金额: $ 3.33万
• 依托单位: Yokohama City University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2011
• 资助国家: 日本
• 起止时间: 2011 至 2013
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23591546/
• 关键词: 小児免疫学; 小児免疫・アレルギー・膠原病学

Growth impairment accompanied with systemic juvenile idiopathic arthritis (sJIA) is thought to be associated with suppression of proliferation of chondrocyte by IL-6, the key cytokine causing systemic inflammation, and suppression of bone extension by corticosteroid. Tocilizumab, anti-IL-6 receptor antibody, was approved in 2008 in Japan, so now bloadly used as treatment for steroid-refractory or -dependent sJIA. We have investigated height and height velocity of 45 sJIA patient administered with TCZ and analyzed correlation between them and several factors such as age, gender, disease duration and corticosteroid exposure, then inverse correlation between standard deviation score for height (HTSDS) and disease duration and strong correlation between reduction of corticosteroid and improvement of height velocity.

全身性幼年特发性关节炎（sJIA）伴发的生长障碍被认为与IL-6（引起全身性炎症的关键细胞因子）抑制软骨细胞增殖和皮质类固醇抑制骨延伸有关。Tocilizumab是一种抗IL-6受体抗体，2008年在日本获得批准，目前主要用于治疗激素难治性或依赖性sJIA。对45例sJIA患者应用TCZ治疗后的身高和身高增长速度进行了调查，分析了其与年龄、性别、病程、激素用量等因素的相关性，身高标准差评分（HTSDS）与病程呈负相关，激素减量与身高增长速度改善呈强相关。

项目成果

Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan.

• DOI: 10.1007/s10067-012-2082-5
• 发表时间: 2012-12
• 期刊: CLINICAL RHEUMATOLOGY
• 影响因子: 3.4
• 作者: Imagawa, Tomoyuki;Takei, Syuji;Umebayashi, Hiroaki;Yamaguchi, Kenichi;Itoh, Yasuhiko;Kawai, Toshinao;Iwata, Naomi;Murata, Takuji;Okafuji, Ikuo;Miyoshi, Mari;Onoe, Yasuhiro;Kawano, Yoshifumi;Kinjo, Noriko;Mori, Masaaki;Mozaffarian, Neelufar;Kupper, Hartmut;Santra, Sourav;Patel, Gina;Kawai, Shinichi;Yokota, Shumpei
• 通讯作者: Yokota, Shumpei

Definitive differences in laboratory and radiological characteristics between two subtypes of juvenile idiopathic arthritis: systemic arthritis and polyarthritis

• DOI: 10.1007/s10165-011-0540-6
• 发表时间: 2012-08-01
• 期刊: MODERN RHEUMATOLOGY
• 影响因子: 2.2
• 作者: Ozawa, Remi;Inaba, Yutaka;Yokota, Shumpei
• 通讯作者: Yokota, Shumpei

Recent Advances in Pediatric Rheumatic Diseases from the Viewpoint of Dysregulation of Proinflammatory Cytokines

从促炎细胞因子失调的角度看小儿风湿性疾病的最新进展

• 发表时间: 2013
• 作者: Ozawa R;Inaba Y;Mori M;Hara R;Kikuchi M;Higuchi R;Miyamae T;Imagawa T;Fujiwara T;Saito T;Yokota S;Ozawa R,Inaba Y,Mori M,Hara R,Kikuchi M,Miyamae T,Imagawa T,Yokota s;Yokota S.
• 通讯作者: Yokota S.

Definitive differences inn laboratory and radiological characteristics between two subtypes of juvenile idiopathic arthritis:systemic arthiritis and polyarthritis

幼年特发性关节炎两种亚型：系统性关节炎和多发性关节炎在实验室和放射学特征上的明确差异

• 发表时间: 2011
• 期刊: Mod Rheumatol
• 影响因子: 2.2
• 作者: Ozawa R;Inaba Y;Mori M;Hara R;Kikuchi M;Higuchi R;Miyamae T;Imagawa T;Fujiwara T;Saito T;Yokota S;Ozawa R,Inaba Y,Mori M,Hara R,Kikuchi M,Miyamae T,Imagawa T,Yokota s
• 通讯作者: Ozawa R,Inaba Y,Mori M,Hara R,Kikuchi M,Miyamae T,Imagawa T,Yokota s

Effect of Tocilizumab on growth impairment in systemic juvenile idiopathic arthritis with long-term corticosteroid therapy

托珠单抗对长期皮质类固醇治疗的全身性幼年特发性关节炎生长障碍的影响

• 发表时间: 2013
• 期刊: Mod Rheumatol
• 影响因子: 2.2
• 作者: Miyamae T;Yokoya S;Yamanaka H;Yokota S.
• 通讯作者: Yokota S.